Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Profound Medical (PROF : NSDQ)

• Company Description    Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R) platforms. Profound Medical Corp. is based in Mississauga, Canada. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $5.81 Daily Weekly Monthly 20 Day Moving Average: 26,633 shares Shares Outstanding: 30.05 (millions) Market Capitalization: $174.61 (millions) Beta: 0.49 52 Week High: $11.42 52 Week Low: $3.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.21% -11.36% 12 Week 21.55% 2.58% Year To Date -22.64% -24.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2400 SKYMARK AVENUE UNIT 6 - MISSISSAUGA,A6 L4W 5K5 CAN ph: 64-7476-1350 fax: 64-7847-3739 skilmer@profoundmedical.com http://www.profoundmedical.com

• General Corporate Information    Officers Arun Menawats - Chief Executive Officer and Director Rashed Dewan - Chief Financial Officer Brian Ellacott - Director Cynthia Lavoie - Director Murielle Lortie - Director Peer Information Profound Medical (GSAC) Profound Medical (CASI) Profound Medical (ALCD.) Profound Medical (OMNN) Profound Medical (CGPI.) Profound Medical (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74319B502 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 30.05 Most Recent Split Date: (:1) Beta: 0.49 Market Capitalization: $174.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.44 Price/Cash Flow: - Price / Sales: 14.72 EPS Growth vs. Year Ago Period: -38.46% vs. Previous Quarter: -80.00% Sales Growth vs. Year Ago Period: 37.23% vs. Previous Quarter: -37.25% ROE 06/30/25 - - 03/31/25 - -70.41 12/31/24 - -62.13 ROA 06/30/25 - - 03/31/25 - -57.22 12/31/24 - -49.90 Current Ratio 06/30/25 - - 03/31/25 - 11.31 12/31/24 - 10.52 Quick Ratio 06/30/25 - - 03/31/25 - 10.03 12/31/24 - 9.64 Operating Margin 06/30/25 - - 03/31/25 - -269.35 12/31/24 - -245.95 Net Margin 06/30/25 - - 03/31/25 - -269.35 12/31/24 - -245.95 Pre-Tax Margin 06/30/25 - - 03/31/25 - -269.38 12/31/24 - -260.47 Book Value 06/30/25 - - 03/31/25 - 1.69 12/31/24 - 2.01 Inventory Turnover 06/30/25 - - 03/31/25 - 0.60 12/31/24 - 0.56 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.09 12/31/24 - 0.05 Debt-to-Capital 06/30/25 - - 03/31/25 - 8.12 12/31/24 - 4.62

Powered by Zacks Investment Research ©